Saltar al contenido
MilliporeSigma

Serotonin 2C receptor antagonists induce fast-onset antidepressant effects.

Molecular psychiatry (2013-10-30)
M D Opal, S C Klenotich, M Morais, J Bessa, J Winkle, D Doukas, L J Kay, N Sousa, S M Dulawa
RESUMEN

Current antidepressants must be administered for several weeks to produce therapeutic effects. We show that selective serotonin 2C (5-HT2C) antagonists exert antidepressant actions with a faster-onset (5 days) than that of current antidepressants (14 days) in mice. Subchronic (5 days) treatment with 5-HT2C antagonists induced antidepressant behavioral effects in the chronic forced swim test (cFST), chronic mild stress (CMS) paradigm and olfactory bulbectomy paradigm. This treatment regimen also induced classical markers of antidepressant action: activation of cAMP response element-binding protein (CREB) and induction of brain-derived neurotrophic factor (BDNF) in the medial prefrontal cortex (mPFC). None of these effects were induced by subchronic treatment with citalopram, a prototypical selective serotonin reuptake inhibitor (SSRI). Local infusion of 5-HT2C antagonists into the ventral tegmental area was sufficient to induce BDNF in the mPFC, and dopamine D1 receptor antagonist treatment blocked the antidepressant behavioral effects of 5-HT2C antagonists. 5-HT2C antagonists also activated mammalian target of rapamycin (mTOR) and eukaryotic elongation factor 2 (eEF2) in the mPFC, effects recently linked to rapid antidepressant action. Furthermore, 5-HT2C antagonists reversed CMS-induced atrophy of mPFC pyramidal neurons. Subchronic SSRI treatment, which does not induce antidepressant behavioral effects, also activated mTOR and eEF2 and reversed CMS-induced neuronal atrophy, indicating that these effects are not sufficient for antidepressant onset. Our findings reveal that 5-HT2C antagonists are putative fast-onset antidepressants, which act through enhancement of mesocortical dopaminergic signaling.

MATERIALES
Referencia del producto
Marca
Descripción del producto

Sigma-Aldrich
Fluoxetina hydrochloride, solid
Sigma-Aldrich
Citalopram hydrobromide, ≥98% (HPLC)
USP
Fluoxetina hydrochloride, United States Pharmacopeia (USP) Reference Standard
Supelco
Fluoxetina hydrochloride, Pharmaceutical Secondary Standard; Certified Reference Material
USP
Citalopram hydrobromide, United States Pharmacopeia (USP) Reference Standard
Supelco
Fluoxetina hydrochloride, VETRANAL®, analytical standard
Citalopram hydrobromide, European Pharmacopoeia (EP) Reference Standard
Citalopram for system suitability, European Pharmacopoeia (EP) Reference Standard